SEC EDGARNOV 4$ASPE

ORBIMED ADVISORS LLC purchased $15.0M of ASPE (indirect holdings)

ORBIMED ADVISORS LLC purchased 1,000,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($15.00M total) on 2026-11-02. Filed jointly with OrbiMed Capital GP VII LLC (Director).

Original reporting

SEC EDGAR · ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC

Published Nov 4, 2026, 11:43 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 4, 2026, 11:53 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ASPE

Bullish

high confidence

Mentioned

$ASPE

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ASPEBullishMed

Why it matters

The transaction reflects confidence from a major shareholder and may influence short‑term price dynamics.

Market read

First‑report insider purchase of $15 M could act as a catalyst for ASPE's stock, with potential spillover to the biotech sector.

What to watch

Potential dilution from future financing rounds may offset the positive signal.

Relevance 8/10Novelty 8/10Timing: today

Background

SEC Form 4 filing discloses an insider's open‑market purchase of Aspen Neuroscience shares.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ASPEBullishHigh confidence

Context

Director and 10% owner OrbiMed Advisors LLC bought 1,000,000 shares of Aspen Neuroscience at $15.00 each, increasing its stake to 3,589,132 shares.

Expected impact

upward pressure as the market prices in the insider buying

Evidence & confidence

A $15 M open‑market purchase by a director signals strong belief in the company's future, which typically drives buying interest.

Market effects

Sector

Positive signal for the biotech sector, may lift peer sentiment.

Regional

Limited to U.S. markets where ASPE trades.

Global

Minor; primarily affects investors tracking biotech insider activity.

Counterpoint

What could challenge this read

The purchase could be a defensive move ahead of upcoming clinical trial risk.

Key entities

company
Aspen Neuroscience, Inc.
Biotech firm developing neuroscience therapies.
investor
OrbiMed Advisors LLC
Healthcare-focused investment firm; director and 10% owner of Aspen Neuroscience.

Read at source ← All news

NOV 4

$ASPEMedAI 8/10

Thompson Peter A. purchased $15.0M of ASPE (indirect holdings)

Thompson Peter A. purchased 1,000,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($15.00M total) on 2026-11-02.

SEC EDGAR

NOV 3

$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR

NOV 3

$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR

NOV 3

$ASPEMedAI 8/10

ARCH Venture Partners XIV, L.P. (BERNS PAUL L) purchased $18.0M of ASPE

ARCH Venture Partners XIV, L.P. purchased 1,200,000 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Partners XIV, LLC (10% owner), ARCH Venture Fund XIV, L.P. (10% owner) and BERNS PAUL L (10% owner).

SEC EDGAR

NOV 2

$ASPEHighAI 9/10

Aspen Neuroscience, Inc. (ASPE): Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year

Aspen Neuroscience, Inc. (ASPE) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year. On November 2, 2026, in connection with the closing of the initial public offering (the “ IPO ”) of Aspen Neuroscience, Inc. (the “ Company ”), the Company’s amended and restated certificate of

SEC EDGAR 8-K

OCT 30

$ASPEMedAI 8/10

Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO

Aspen Neuroscience plans to raise $140.6M via IPO, offering 9.375M shares at $15 each. The company, developing Parkinson's disease cell therapy sasineprocel, will list on Nasdaq under ASPE. Proceeds will fund clinical trials and working capital. The company reported a $36.5M net loss for the first half of 2026.

tradingview.com

ORBIMED ADVISORS LLC purchased $15.0M of ASPE (indirect holdings)

The 30-second read

Why it matters

Market read

What to watch

Background

Ticker impact

Market effects

Counterpoint

Key entities

Full insider trading history

Related articles

Thompson Peter A. purchased $15.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Partners XIV, L.P. (BERNS PAUL L) purchased $18.0M of ASPE

Aspen Neuroscience, Inc. (ASPE): Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year

Aspen Neuroscience, Autologous Cell Therapies for Neurological Disease, Files for Nasdaq IPO